カテゴリー： Market Monitor Global, 世界, 医療/バイオ

がん最小残存病変検査の世界市場見通し2023年-2029年

◆英語タイトル：Cancer Minimal Residual Disease Testing Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが発行した調査報告書（MMG23FB2253）

◆商品コード：MMG23FB2253
◆発行会社（リサーチ会社）：Market Monitor Global
◆発行日：2023年2月
◆ページ数：118
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後2-3営業日）
◆調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
◆産業分野：医療機器

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,250 ⇒換算￥494,000	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD4,225 ⇒換算￥642,200	見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）	USD4,875 ⇒換算￥741,000	見積依頼/購入/質問フォーム

★Market Monitor Globalに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

当調査レポートは次の情報を含め、世界のがん最小残存病変検査市場規模と予測を収録しています。・世界のがん最小残存病変検査市場：売上、2018年-2023年、2024年-2029年
・世界のがん最小残存病変検査市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界のがん最小残存病変検査市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「フローサイトメトリー」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

がん最小残存病変検査のグローバル主要企業は、Adaptive Biotechnologies Corporation、ArcherDX, Inc. (Invitae Corporation)、Asuragen、Arup Laboratories、Bio-Rad Laboratories、Cergentis B.V.、F. Hoffmann- La Roche Ltd、Guardant Health、ICON plc、Invivoscribe、Laboratory Corporation of America Holdings、Mission Bio、Natera, Inc.、NeoGenomics Laboratories、Opko Health、Quest Diagnostics Incorporated、Sysmex Corporation、Genetron Healthなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、がん最小残存病変検査のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界のがん最小残存病変検査市場：タイプ別、2018年-2023年、2024年-2029年
世界のがん最小残存病変検査市場：タイプ別市場シェア、2022年
・フローサイトメトリー、ポリメラーゼ連鎖反応（PCR）、次世代シーケンシング（NGS）、その他

世界のがん最小残存病変検査市場：用途別、2018年-2023年、2024年-2029年
世界のがん最小残存病変検査市場：用途別市場シェア、2022年
・血液悪性腫瘍、白血病、リンパ腫、固形腫瘍、その他

世界のがん最小残存病変検査市場：地域・国別、2018年-2023年、2024年-2029年
世界のがん最小残存病変検査市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業におけるがん最小残存病変検査のグローバル売上、2018年-2023年
・主要企業におけるがん最小残存病変検査のグローバル売上シェア、2022年
・主要企業におけるがん最小残存病変検査のグローバル販売量、2018年-2023年
・主要企業におけるがん最小残存病変検査のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
Adaptive Biotechnologies Corporation、ArcherDX, Inc. (Invitae Corporation)、Asuragen、Arup Laboratories、Bio-Rad Laboratories、Cergentis B.V.、F. Hoffmann- La Roche Ltd、Guardant Health、ICON plc、Invivoscribe、Laboratory Corporation of America Holdings、Mission Bio、Natera, Inc.、NeoGenomics Laboratories、Opko Health、Quest Diagnostics Incorporated、Sysmex Corporation、Genetron Health

*************************************************************

・調査・分析レポートの概要
がん最小残存病変検査市場の定義
市場セグメント
世界のがん最小残存病変検査市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界のがん最小残存病変検査市場規模
世界のがん最小残存病変検査市場規模：2022年 VS 2029年
世界のがん最小残存病変検査市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでのがん最小残存病変検査の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業のがん最小残存病変検査製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：フローサイトメトリー、ポリメラーゼ連鎖反応（PCR）、次世代シーケンシング（NGS）、その他
がん最小残存病変検査のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：血液悪性腫瘍、白血病、リンパ腫、固形腫瘍、その他
がん最小残存病変検査の用途別グローバル売上・予測

・地域別市場分析
地域別がん最小残存病変検査市場規模 2022年と2029年
地域別がん最小残存病変検査売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
Adaptive Biotechnologies Corporation、ArcherDX, Inc. (Invitae Corporation)、Asuragen、Arup Laboratories、Bio-Rad Laboratories、Cergentis B.V.、F. Hoffmann- La Roche Ltd、Guardant Health、ICON plc、Invivoscribe、Laboratory Corporation of America Holdings、Mission Bio、Natera, Inc.、NeoGenomics Laboratories、Opko Health、Quest Diagnostics Incorporated、Sysmex Corporation、Genetron Health
...

Minimal residual disease (MRD) is a term used to describe the small number of cancer cells in the body after cancer treatment. An MRD positive test result means that disease was still detected after treatment. An MRD negative result means that no disease was detected after treatment.
This report aims to provide a comprehensive presentation of the global market for Cancer Minimal Residual Disease Testing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Minimal Residual Disease Testing. This report contains market size and forecasts of Cancer Minimal Residual Disease Testing in global, including the following market information:
Global Cancer Minimal Residual Disease Testing Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Cancer Minimal Residual Disease Testing Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Cancer Minimal Residual Disease Testing companies in 2022 (%)
The global Cancer Minimal Residual Disease Testing market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Flow Cytometry Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Cancer Minimal Residual Disease Testing include Adaptive Biotechnologies Corporation, ArcherDX, Inc. (Invitae Corporation), Asuragen, Arup Laboratories, Bio-Rad Laboratories, Cergentis B.V., F. Hoffmann- La Roche Ltd, Guardant Health and ICON plc, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Cancer Minimal Residual Disease Testing manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
[Total Market by Segment]
Global Cancer Minimal Residual Disease Testing Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Cancer Minimal Residual Disease Testing Market Segment Percentages, by Type, 2022 (%)
Flow Cytometry
Polymerase Chain Reaction (PCR)
Next-Generation Sequencing (NGS)
Other
Global Cancer Minimal Residual Disease Testing Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Cancer Minimal Residual Disease Testing Market Segment Percentages, by Application, 2022 (%)
Hematological Malignancies
Leukemia
Lymphoma
Solid Tumors
Other
Global Cancer Minimal Residual Disease Testing Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Cancer Minimal Residual Disease Testing Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Cancer Minimal Residual Disease Testing revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Cancer Minimal Residual Disease Testing revenues share in global market, 2022 (%)
Key companies Cancer Minimal Residual Disease Testing sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Cancer Minimal Residual Disease Testing sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Adaptive Biotechnologies Corporation
ArcherDX, Inc. (Invitae Corporation)
Asuragen
Arup Laboratories
Bio-Rad Laboratories
Cergentis B.V.
F. Hoffmann- La Roche Ltd
Guardant Health
ICON plc
Invivoscribe
Laboratory Corporation of America Holdings
Mission Bio
Natera, Inc.
NeoGenomics Laboratories
Opko Health
Quest Diagnostics Incorporated
Sysmex Corporation
Genetron Health
Outline of Major Chapters:
Chapter 1: Introduces the definition of Cancer Minimal Residual Disease Testing, market overview.
Chapter 2: Global Cancer Minimal Residual Disease Testing market size in revenue and volume.
Chapter 3: Detailed analysis of Cancer Minimal Residual Disease Testing manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Cancer Minimal Residual Disease Testing in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Cancer Minimal Residual Disease Testing capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Cancer Minimal Residual Disease Testing Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Cancer Minimal Residual Disease Testing Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Cancer Minimal Residual Disease Testing Overall Market Size
2.1 Global Cancer Minimal Residual Disease Testing Market Size: 2022 VS 2029
2.2 Global Cancer Minimal Residual Disease Testing Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Cancer Minimal Residual Disease Testing Sales: 2018-2029
3 Company Landscape
3.1 Top Cancer Minimal Residual Disease Testing Players in Global Market
3.2 Top Global Cancer Minimal Residual Disease Testing Companies Ranked by Revenue
3.3 Global Cancer Minimal Residual Disease Testing Revenue by Companies
3.4 Global Cancer Minimal Residual Disease Testing Sales by Companies
3.5 Global Cancer Minimal Residual Disease Testing Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Cancer Minimal Residual Disease Testing Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Cancer Minimal Residual Disease Testing Product Type
3.8 Tier 1, Tier 2 and Tier 3 Cancer Minimal Residual Disease Testing Players in Global Market
3.8.1 List of Global Tier 1 Cancer Minimal Residual Disease Testing Companies
3.8.2 List of Global Tier 2 and Tier 3 Cancer Minimal Residual Disease Testing Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Cancer Minimal Residual Disease Testing Market Size Markets, 2022 & 2029
4.1.2 Flow Cytometry
4.1.3 Polymerase Chain Reaction (PCR)
4.1.4 Next-Generation Sequencing (NGS)
4.1.5 Other
4.2 By Type – Global Cancer Minimal Residual Disease Testing Revenue & Forecasts
4.2.1 By Type – Global Cancer Minimal Residual Disease Testing Revenue, 2018-2023
4.2.2 By Type – Global Cancer Minimal Residual Disease Testing Revenue, 2024-2029
4.2.3 By Type – Global Cancer Minimal Residual Disease Testing Revenue Market Share, 2018-2029
4.3 By Type – Global Cancer Minimal Residual Disease Testing Sales & Forecasts
4.3.1 By Type – Global Cancer Minimal Residual Disease Testing Sales, 2018-2023
4.3.2 By Type – Global Cancer Minimal Residual Disease Testing Sales, 2024-2029
4.3.3 By Type – Global Cancer Minimal Residual Disease Testing Sales Market Share, 2018-2029
4.4 By Type – Global Cancer Minimal Residual Disease Testing Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Cancer Minimal Residual Disease Testing Market Size, 2022 & 2029
5.1.2 Hematological Malignancies
5.1.3 Leukemia
5.1.4 Lymphoma
5.1.5 Solid Tumors
5.1.6 Other
5.2 By Application – Global Cancer Minimal Residual Disease Testing Revenue & Forecasts
5.2.1 By Application – Global Cancer Minimal Residual Disease Testing Revenue, 2018-2023
5.2.2 By Application – Global Cancer Minimal Residual Disease Testing Revenue, 2024-2029
5.2.3 By Application – Global Cancer Minimal Residual Disease Testing Revenue Market Share, 2018-2029
5.3 By Application – Global Cancer Minimal Residual Disease Testing Sales & Forecasts
5.3.1 By Application – Global Cancer Minimal Residual Disease Testing Sales, 2018-2023
5.3.2 By Application – Global Cancer Minimal Residual Disease Testing Sales, 2024-2029
5.3.3 By Application – Global Cancer Minimal Residual Disease Testing Sales Market Share, 2018-2029
5.4 By Application – Global Cancer Minimal Residual Disease Testing Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Cancer Minimal Residual Disease Testing Market Size, 2022 & 2029
6.2 By Region – Global Cancer Minimal Residual Disease Testing Revenue & Forecasts
6.2.1 By Region – Global Cancer Minimal Residual Disease Testing Revenue, 2018-2023
6.2.2 By Region – Global Cancer Minimal Residual Disease Testing Revenue, 2024-2029
6.2.3 By Region – Global Cancer Minimal Residual Disease Testing Revenue Market Share, 2018-2029
6.3 By Region – Global Cancer Minimal Residual Disease Testing Sales & Forecasts
6.3.1 By Region – Global Cancer Minimal Residual Disease Testing Sales, 2018-2023
6.3.2 By Region – Global Cancer Minimal Residual Disease Testing Sales, 2024-2029
6.3.3 By Region – Global Cancer Minimal Residual Disease Testing Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Cancer Minimal Residual Disease Testing Revenue, 2018-2029
6.4.2 By Country – North America Cancer Minimal Residual Disease Testing Sales, 2018-2029
6.4.3 US Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.4.4 Canada Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.4.5 Mexico Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Cancer Minimal Residual Disease Testing Revenue, 2018-2029
6.5.2 By Country – Europe Cancer Minimal Residual Disease Testing Sales, 2018-2029
6.5.3 Germany Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.5.4 France Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.5.5 U.K. Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.5.6 Italy Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.5.7 Russia Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.5.8 Nordic Countries Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.5.9 Benelux Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Cancer Minimal Residual Disease Testing Revenue, 2018-2029
6.6.2 By Region – Asia Cancer Minimal Residual Disease Testing Sales, 2018-2029
6.6.3 China Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.6.4 Japan Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.6.5 South Korea Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.6.6 Southeast Asia Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.6.7 India Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Cancer Minimal Residual Disease Testing Revenue, 2018-2029
6.7.2 By Country – South America Cancer Minimal Residual Disease Testing Sales, 2018-2029
6.7.3 Brazil Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.7.4 Argentina Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Cancer Minimal Residual Disease Testing Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Cancer Minimal Residual Disease Testing Sales, 2018-2029
6.8.3 Turkey Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.8.4 Israel Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.8.5 Saudi Arabia Cancer Minimal Residual Disease Testing Market Size, 2018-2029
6.8.6 UAE Cancer Minimal Residual Disease Testing Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Adaptive Biotechnologies Corporation
7.1.1 Adaptive Biotechnologies Corporation Company Summary
7.1.2 Adaptive Biotechnologies Corporation Business Overview
7.1.3 Adaptive Biotechnologies Corporation Cancer Minimal Residual Disease Testing Major Product Offerings
7.1.4 Adaptive Biotechnologies Corporation Cancer Minimal Residual Disease Testing Sales and Revenue in Global (2018-2023)
7.1.5 Adaptive Biotechnologies Corporation Key News & Latest Developments
7.2 ArcherDX, Inc. (Invitae Corporation)
7.2.1 ArcherDX, Inc. (Invitae Corporation) Company Summary
7.2.2 ArcherDX, Inc. (Invitae Corporation) Business Overview
7.2.3 ArcherDX, Inc. (Invitae Corporation) Cancer Minimal Residual Disease Testing Major Product Offerings
7.2.4 ArcherDX, Inc. (Invitae Corporation) Cancer Minimal Residual Disease Testing Sales and Revenue in Global (2018-2023)
7.2.5 ArcherDX, Inc. (Invitae Corporation) Key News & Latest Developments
7.3 Asuragen
7.3.1 Asuragen Company Summary
7.3.2 Asuragen Business Overview
7.3.3 Asuragen Cancer Minimal Residual Disease Testing Major Product Offerings
7.3.4 Asuragen Cancer Minimal Residual Disease Testing Sales and Revenue in Global (2018-2023)
7.3.5 Asuragen Key News & Latest Developments
7.4 Arup Laboratories
7.4.1 Arup Laboratories Company Summary
7.4.2 Arup Laboratories Business Overview
7.4.3 Arup Laboratories Cancer Minimal Residual Disease Testing Major Product Offerings
7.4.4 Arup Laboratories Cancer Minimal Residual Disease Testing Sales and Revenue in Global (2018-2023)
7.4.5 Arup Laboratories Key News & Latest Developments
7.5 Bio-Rad Laboratories
7.5.1 Bio-Rad Laboratories Company Summary
7.5.2 Bio-Rad Laboratories Business Overview
7.5.3 Bio-Rad Laboratories Cancer Minimal Residual Disease Testing Major Product Offerings
7.5.4 Bio-Rad Laboratories Cancer Minimal Residual Disease Testing Sales and Revenue in Global (2018-2023)
7.5.5 Bio-Rad Laboratories Key News & Latest Developments
7.6 Cergentis B.V.
7.6.1 Cergentis B.V. Company Summary
7.6.2 Cergentis B.V. Business Overview
7.6.3 Cergentis B.V. Cancer Minimal Residual Disease Testing Major Product Offerings
7.6.4 Cergentis B.V. Cancer Minimal Residual Disease Testing Sales and Revenue in Global (2018-2023)
7.6.5 Cergentis B.V. Key News & Latest Developments
7.7 F. Hoffmann- La Roche Ltd
7.7.1 F. Hoffmann- La Roche Ltd Company Summary
7.7.2 F. Hoffmann- La Roche Ltd Business Overview
7.7.3 F. Hoffmann- La Roche Ltd Cancer Minimal Residual Disease Testing Major Product Offerings
7.7.4 F. Hoffmann- La Roche Ltd Cancer Minimal Residual Disease Testing Sales and Revenue in Global (2018-2023)
7.7.5 F. Hoffmann- La Roche Ltd Key News & Latest Developments
7.8 Guardant Health
7.8.1 Guardant Health Company Summary
7.8.2 Guardant Health Business Overview
7.8.3 Guardant Health Cancer Minimal Residual Disease Testing Major Product Offerings
7.8.4 Guardant Health Cancer Minimal Residual Disease Testing Sales and Revenue in Global (2018-2023)
7.8.5 Guardant Health Key News & Latest Developments
7.9 ICON plc
7.9.1 ICON plc Company Summary
7.9.2 ICON plc Business Overview
7.9.3 ICON plc Cancer Minimal Residual Disease Testing Major Product Offerings
7.9.4 ICON plc Cancer Minimal Residual Disease Testing Sales and Revenue in Global (2018-2023)
7.9.5 ICON plc Key News & Latest Developments
7.10 Invivoscribe
7.10.1 Invivoscribe Company Summary
7.10.2 Invivoscribe Business Overview
7.10.3 Invivoscribe Cancer Minimal Residual Disease Testing Major Product Offerings
7.10.4 Invivoscribe Cancer Minimal Residual Disease Testing Sales and Revenue in Global (2018-2023)
7.10.5 Invivoscribe Key News & Latest Developments
7.11 Laboratory Corporation of America Holdings
7.11.1 Laboratory Corporation of America Holdings Company Summary
7.11.2 Laboratory Corporation of America Holdings Cancer Minimal Residual Disease Testing Business Overview
7.11.3 Laboratory Corporation of America Holdings Cancer Minimal Residual Disease Testing Major Product Offerings
7.11.4 Laboratory Corporation of America Holdings Cancer Minimal Residual Disease Testing Sales and Revenue in Global (2018-2023)
7.11.5 Laboratory Corporation of America Holdings Key News & Latest Developments
7.12 Mission Bio
7.12.1 Mission Bio Company Summary
7.12.2 Mission Bio Cancer Minimal Residual Disease Testing Business Overview
7.12.3 Mission Bio Cancer Minimal Residual Disease Testing Major Product Offerings
7.12.4 Mission Bio Cancer Minimal Residual Disease Testing Sales and Revenue in Global (2018-2023)
7.12.5 Mission Bio Key News & Latest Developments
7.13 Natera, Inc.
7.13.1 Natera, Inc. Company Summary
7.13.2 Natera, Inc. Cancer Minimal Residual Disease Testing Business Overview
7.13.3 Natera, Inc. Cancer Minimal Residual Disease Testing Major Product Offerings
7.13.4 Natera, Inc. Cancer Minimal Residual Disease Testing Sales and Revenue in Global (2018-2023)
7.13.5 Natera, Inc. Key News & Latest Developments
7.14 NeoGenomics Laboratories
7.14.1 NeoGenomics Laboratories Company Summary
7.14.2 NeoGenomics Laboratories Business Overview
7.14.3 NeoGenomics Laboratories Cancer Minimal Residual Disease Testing Major Product Offerings
7.14.4 NeoGenomics Laboratories Cancer Minimal Residual Disease Testing Sales and Revenue in Global (2018-2023)
7.14.5 NeoGenomics Laboratories Key News & Latest Developments
7.15 Opko Health
7.15.1 Opko Health Company Summary
7.15.2 Opko Health Business Overview
7.15.3 Opko Health Cancer Minimal Residual Disease Testing Major Product Offerings
7.15.4 Opko Health Cancer Minimal Residual Disease Testing Sales and Revenue in Global (2018-2023)
7.15.5 Opko Health Key News & Latest Developments
7.16 Quest Diagnostics Incorporated
7.16.1 Quest Diagnostics Incorporated Company Summary
7.16.2 Quest Diagnostics Incorporated Business Overview
7.16.3 Quest Diagnostics Incorporated Cancer Minimal Residual Disease Testing Major Product Offerings
7.16.4 Quest Diagnostics Incorporated Cancer Minimal Residual Disease Testing Sales and Revenue in Global (2018-2023)
7.16.5 Quest Diagnostics Incorporated Key News & Latest Developments
7.17 Sysmex Corporation
7.17.1 Sysmex Corporation Company Summary
7.17.2 Sysmex Corporation Business Overview
7.17.3 Sysmex Corporation Cancer Minimal Residual Disease Testing Major Product Offerings
7.17.4 Sysmex Corporation Cancer Minimal Residual Disease Testing Sales and Revenue in Global (2018-2023)
7.17.5 Sysmex Corporation Key News & Latest Developments
7.18 Genetron Health
7.18.1 Genetron Health Company Summary
7.18.2 Genetron Health Business Overview
7.18.3 Genetron Health Cancer Minimal Residual Disease Testing Major Product Offerings
7.18.4 Genetron Health Cancer Minimal Residual Disease Testing Sales and Revenue in Global (2018-2023)
7.18.5 Genetron Health Key News & Latest Developments
8 Global Cancer Minimal Residual Disease Testing Production Capacity, Analysis
8.1 Global Cancer Minimal Residual Disease Testing Production Capacity, 2018-2029
8.2 Cancer Minimal Residual Disease Testing Production Capacity of Key Manufacturers in Global Market
8.3 Global Cancer Minimal Residual Disease Testing Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Cancer Minimal Residual Disease Testing Supply Chain Analysis
10.1 Cancer Minimal Residual Disease Testing Industry Value Chain
10.2 Cancer Minimal Residual Disease Testing Upstream Market
10.3 Cancer Minimal Residual Disease Testing Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Cancer Minimal Residual Disease Testing Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ がん最小残存病変検査の世界市場見通し2023年-2029年(Cancer Minimal Residual Disease Testing Market, Global Outlook and Forecast 2023-2029)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

がん最小残存病変検査の世界市場見通し2023年-2029年

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp